Artículos por temáticas

Biomarker treatment effects in two phase 3 trials of gantenerumab

Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, Delmar P, Scelsi MA, Gobbi S, Silvestri E, Barakovic M, Napolitano A, Galli C, Abaei M, Blennow K, Barkhof F.

Alzheimers Dement. 2025 Feb;21(2):e14414. doi: 10.1002/alz.14414. Epub 2025 Jan 30.

Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study

Zúñiga CH, Acosta BI, Menchaca R, Amescua CA, Hong S, Hui L, Gil M, Rhee YH, Yoon S, Kim M, Chang PY, Kim YM, Song PY, Betito K.

Alzheimers Res Ther. 2025 Feb 12;17(1):40. doi: 10.1186/s13195-025-01681-2.

Testing the iMplementation Framework fOr behavioral and LIfestyLe interventions in AlZheimer's DiseasE (MOBILIZE) via the ACT randomized controlled trial

Salisbury DL, Lin FV, Yu F.

Sci Rep. 2025 Feb 13;15(1):5341. doi: 10.1038/s41598-025-88890-9.

Pre-treatment subjective sleep quality as a predictive biomarker of tDCS effects in preclinical Alzheimer's disease patients: Secondary analysis of a randomised clinical trial

Lu H, Ni X, Man Chan SS, Cheng CPW, Chan W, Lam LCW.

PLoS One. 2025 Jan 28;20(1):e0317700. doi: 10.1371/journal.pone.0317700. eCollection 2025.

Beta-site APP-cleaving Enzyme-1 Inhibitory Role of Natural Flavonoids in the Treatment of Alzheimer's Disease

Singh S, Kushwaha V, Sisodia S, Kumar S, Sahu KK.

Cent Nerv Syst Agents Med Chem. 2025;25(1):39-48. doi: 10.2174/0118715249315049240710063455.

High definition transcranial direct current stimulation as an intervention for cognitive deficits in Alzheimer's dementia: A randomized controlled trial

LoBue C, Chiang HS, Salter A, McClintock S, Nguyen TP, Logan R, Smernoff E, Pandya S, Hart J.

J Prev Alzheimers Dis. 2025 Feb;12(2):100023. doi: 10.1016/j.tjpad.2024.100023. Epub 2025 Jan 1.

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease

Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, León T, Scheltens P.

Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7.

Exploring the role of T cells in Alzheimer's and other neurodegenerative diseases: Emerging therapeutic insights from the T Cells in the Brain symposium

Elyaman W, Stern LJ, Jiang N, Dressman D, Bradley P, Klatzmann D, Bradshaw EM, Farber DL, Kent SC, Chizari S, Funk K, Devanand D, Thakur KT, Raj T, Dalahmah OA, Sarkis RA, Weiner HL, Shneider NA, Prze

Alzheimers Dement. 2025 Feb;21(2):e14548. doi: 10.1002/alz.14548. Epub 2025 Jan 27.

Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial

Ayasse ND, Stewart WF, Lipton RB, Gomez-Ulloa D, Runken MC.

Curr Alzheimer Res. 2025;21(5):353-365. doi: 10.2174/0115672050316936240905064215.

Deoxyvasicinone hybrids in the management of Alzheimer's disease: Recent advances on manmade derivatives, pharmacological activities, and structure-activity relationship

Gaur A, Singh YP, Sharma R, Bainsal N.

Arch Pharm (Weinheim). 2025 Jan;358(1):e2400742. doi: 10.1002/ardp.202400742.

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, Zhang H, Jerecic J, Honig LS, Salloway S, Sperling R, Trame MN, Dodds MG, Johnson K.

J Prev Alzheimers Dis. 2025 Jan;12(1):100005. doi: 10.1016/j.tjpad.2024.100005. Epub 2025 Jan 1.

Playing Around the Coumarin Core in the Discovery of Multimodal Compounds Directed at Alzheimer's-Related Targets: A Recent Literature Overview

Rullo M, La Spada G, Stefanachi A, Macchia E, Pisani L, Leonetti F.

Molecules. 2025 Feb 14;30(4):891. doi: 10.3390/molecules30040891.

Current Developments in Alzheimer's Disease

Goetzl EJ.

Am J Med. 2025 Jan;138(1):15-20. doi: 10.1016/j.amjmed.2024.08.019. Epub 2024 Aug 27.

Recent Insights into the Neurobiology of Alzheimer's Disease and Advanced Treatment Strategies

Anitha K, Singh MK, Kohat K, Sri Varshini T, Chenchula S, Padmavathi R, Amerneni LS, Vishnu Vardhan K, Mythili Bai K, Chavan MR, Bhatt S.

Mol Neurobiol. 2025 Feb;62(2):2314-2332. doi: 10.1007/s12035-024-04384-1. Epub 2024 Aug 5.

"Current and emerging drug therapies in Alzheimer's disease: A pathophysiological Perspective"

Aparajita A, Jain U, Srivastava P.

Neuroscience. 2025 Jan 26;565:499-518. doi: 10.1016/j.neuroscience.2024.11.078. Epub 2024 Dec 9.